Lagevrio
(Molnupiravir)Phase 3Small molecule
Merck & Co.Molnupiravir is an antiviral medication used to treat mild to moderate COVID-19 in adults at high risk of severe illness. It works by interfering with the virus's ability to copy itself in the body.[1] Lagevrio is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Lagevrio is one of 173 small molecule programs targeting Viral Disease. It is currently in Phase 3.
7
Indications
23
Total Trials
7
Active Trials
172
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Lagevrio
Merck & Co.Phase 3
COVID-19 Vaccine
ModernaPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Rayaldee
OOrganon and Co
Preclinical
Statins
SanofiPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Nadroparin
GSKPreclinical
Calcium
Eli LillyPreclinical
Olokizumab
UCBPreclinical
Interferon-Gamma
SSPP Pharmaclon Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-1912 trials
Show 9 more trials
Influenza2 trials
Tics1 trial
Cohort Study1 trial
TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
Completed·—··NCT05195060·1,178 enrolled
6 more indications
Moderate Hepatic Impairment1 trial
Adult1 trial
Dengue1 trial
Adaptive Dengue Antiviral Platform Trial
Not yet recruiting·OOxford University Clinical Research Unit, Vietnam·Phase 2·NCT06551844·500 enrolled
Respiratory Syncytial Virus (RSV)1 trial
Renal Impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Molnupiravir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company